

# Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/N957ADD76271EN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: N957ADD76271EN

## Abstracts

The 7 major neuropathic pain markets reached a value of US\$ 5.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 8.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.7% during 2024-2034.

The neuropathic pain market has been comprehensively analyzed in IMARC's new report titled "Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neuropathic pain is a type of chronic pain that is caused by damage or dysfunction of the nerves. Some of the common symptoms include burning, shooting, or tingling sensations, numbness, heightened sensitivity to touch, etc. The pain can be constant or intermittent and may be felt in a specific area or spread throughout the body. Additionally, individuals with neuropathic pain may experience weakness or loss of sensation in the affected areas. The diagnosis typically involves a combination of medical history, physical examination, and tests to determine the presence of neuropathic pain. During a physical exam, the healthcare provider may look for signs of nerve damage, such as weakness, loss of sensation, or reflex changes, and may perform some tests to assess the function of the affected nerves. Several diagnostic tests, including nerve conduction studies or imaging tests, are done to confirm the presence of nerve damage and identify the specific cause of the pain.

The increasing prevalence of chronic diseases that cause nerve damage and the rising incidences of peripheral nerve injuries are primarily driving the global neuropathic pain market. In addition to this, the inflating usage of anticonvulsants and tricyclic antidepressants for stabilizing nerve cells and reducing the release of certain neurotransmitters is further propelling the market growth. Moreover, the widespread

adoption of nerve blocks, such as epidural injections, for blocking the transmission of pain signals to the brain is also creating a positive outlook for the market. Apart from this, the emerging popularity of transcutaneous electrical nerve stimulation (TENS), a non-invasive pain management therapy that uses low-voltage electrical currents to stimulate nerve fibers and relieve pain, is also bolstering the market growth. Furthermore, the increasing utilization of psychological treatments, including cognitive-behavioral therapy and mindfulness-based interventions, for managing the emotional and psychological aspects of neuropathic pain is acting as another significant growth-inducing factor. Additionally, the rising adoption of nerve stimulation techniques, such as spinal cord stimulation, peripheral nerve stimulation, deep brain stimulation, etc., to alleviate symptoms by stimulating specific nerves or areas of the brain associated with the pain is expected to drive the global neuropathic pain market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the neuropathic pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neuropathic pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neuropathic pain market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain

Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the neuropathic pain market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the neuropathic pain market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current neuropathic pain marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the neuropathic pain market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the neuropathic pain market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the neuropathic pain market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of neuropathic pain across the seven major markets?

What is the number of prevalent cases (2018-2034) of neuropathic pain by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of neuropathic pain by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of neuropathic pain by type across the seven major markets?

How many patients are diagnosed (2018-2034) with neuropathic pain across the seven major markets?

What is the size of the neuropathic pain patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of neuropathic pain?

What will be the growth rate of patients across the seven major markets?

### Neuropathic Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for neuropathic pain drugs across the seven

major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neuropathic pain market?

What are the key regulatory events related to the neuropathic pain market?

What is the structure of clinical trial landscape by status related to the neuropathic pain market?

What is the structure of clinical trial landscape by phase related to the neuropathic pain market?

What is the structure of clinical trial landscape by route of administration related to the neuropathic pain market?

## Contents

### 1 PREFACE

### 2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### 3 EXECUTIVE SUMMARY

### 4 NEUROPATHIC PAIN - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### 5 NEUROPATHIC PAIN - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### 6 PATIENT JOURNEY

### 7 NEUROPATHIC PAIN - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (2018-2034)

- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 NEUROPATHIC PAIN - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 NEUROPATHIC PAIN - UNMET NEEDS**

## **10 NEUROPATHIC PAIN - KEY ENDPOINTS OF TREATMENT**

## **11 NEUROPATHIC PAIN - MARKETED PRODUCTS**

- 11.1 List of Neuropathic Pain Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Lyrica (Pregabalin) - Pfizer
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Nucynta ER (Tapentadol controlled-release) - Grunenthal/Janssen /Ortho-McNeil



- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Cymbalta (Duloxetine) - Eli Lilly and Company
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Qutenza (Capsaicin dermal patch) - Grunenthal
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 NEUROPATHIC PAIN - PIPELINE DRUGS**

### 12.1 List of Neuropathic Pain Pipeline Drugs Across the Top 7 Markets

- 12.1.1 AP 325 - Algiax Pharmaceuticals
  - 12.1.1.1 Drug Overview
  - 12.1.1.2 Mechanism of Action
  - 12.1.1.3 Clinical Trial Results
  - 12.1.1.4 Safety and Efficacy
  - 12.1.1.5 Regulatory Status
- 12.1.2 ACD440 - AlzeCure Pharma
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 Ralfinamide - Newron Pharmaceuticals
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results

- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status
- 12.1.4 Halneuron - WEX Pharmaceuticals
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 LAT 8881 - Lateral Pharma
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results
  - 12.1.5.4 Safety and Efficacy
  - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

### **13. NEUROPATHIC PAIN - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. NEUROPATHIC PAIN – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

### **15 NEUROPATHIC PAIN - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Neuropathic Pain - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Neuropathic Pain - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Neuropathic Pain - Market Size

- 15.3.1.1 Market Size (2018-2023)
- 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Neuropathic Pain - Market Size by Therapies
  - 15.3.2.1 Market Size by Therapies (2018-2023)
  - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Neuropathic Pain - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Neuropathic Pain - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Neuropathic Pain - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Neuropathic Pain - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Neuropathic Pain - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Neuropathic Pain - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Neuropathic Pain - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Neuropathic Pain - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Neuropathic Pain - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Neuropathic Pain - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Neuropathic Pain - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Neuropathic Pain - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Neuropathic Pain - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain

- 15.8.1 Neuropathic Pain - Market Size
  - 15.8.1.1 Market Size (2018-2023)
  - 15.8.1.2 Market Forecast (2024-2034)
- 15.8.2 Neuropathic Pain - Market Size by Therapies
  - 15.8.2.1 Market Size by Therapies (2018-2023)
  - 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Neuropathic Pain - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Neuropathic Pain - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Neuropathic Pain - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Neuropathic Pain - Access and Reimbursement Overview

## **16 NEUROPATHIC PAIN - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 NEUROPATHIC PAIN MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 NEUROPATHIC PAIN MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Neuropathic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/N957ADD76271EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N957ADD76271EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

